Sunday 18 October 2026
Export AFIB’s income statement to Excel — free account
Acutus Medical, Inc.
AFIB Healthcare Medical Devices
In the quarter to December 2024, revenue grew 204.2%, EPS grew 95.9% and free cash flow grew 76.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow AFIB
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 6 | 4 | 3 | 3 | 3 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 4.73 | 4.73 | 38.83 | 5.66 | 13.06 | 0.85 | 0.09 |
Altman Z-Score |
— | — | — | (0.35) | (4.35) | (3.18) | (15.48) | (28.51) |
Altman Z″-Score (non-manufacturers) |
— | (31.23) | (9.12) | (2.87) | (7.73) | (4.43) | (34.40) | (66.67) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | (1.11) | (1.11) | (13.62) | (4.33) | (2.35) | (0.34) | (0.44) |
Beneish M-Score |
— | — | — | — | — | — | — | (2.49) |
P/B ratio |
— | 0.00 | 0.00 | 2.60 | 0.92 | 0.53 | 0.00 | 0.00 |
Price to Tangible BV |
— | 0.00 | 0.00 | 3.02 | 1.10 | 0.54 | 0.00 | 0.00 |
EV/Sales |
— | 7.20 | 7.20 | 28.05 | 2.18 | (0.62) | 1.56 | 1.01 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.86 |
EV/Operating CF |
— | (0.42) | (0.42) | (2.79) | (0.38) | 0.02 | (0.18) | (0.64) |
EV/FCF |
— | (0.38) | (0.38) | (2.46) | (0.34) | 0.02 | (0.18) | (0.64) |
Quick Ratio |
— | 0.73 | 2.26 | 6.09 | 5.65 | 4.74 | 2.15 | 1.76 |
Current Ratio |
— | 0.88 | 2.58 | 6.91 | 6.82 | 5.93 | 2.44 | 2.06 |
Net Debt/EBITDA |
— | (0.25) | 0.63 | 1.06 | 0.59 | (0.75) | (0.43) | 9.90 |
Debt/Assets |
0.00% | 99.68% | 37.06% | 20.75% | 24.04% | 26.04% | 63.97% | 113.69% |
Debt/Equity |
— | (1.92) | 1.42 | 0.32 | 0.39 | 0.46 | (39.27) | (2.81) |
Asset Turnover |
— | 0.17 | 0.04 | 0.06 | 0.10 | 0.02 | 0.08 | 0.49 |
Operating CF/Net income |
— | 0.71 | 0.58 | 0.84 | 0.85 | 2.24 | 0.77 | 3.32 |
Capex/Depreciation |
— | (0.38) | (0.65) | (2.18) | (1.04) | (0.02) | (12.88) | (0.06) |
Interest Coverage |
— | (7.22) | (3.26) | (16.59) | (19.75) | 7.97 | (2.07) | (0.01) |
| — | 26.79% | 54.27% | 205.55% | (101.32%) | (43.84%) | (220.29%) | 153.11% | |
| — | (369.25%) | (147.70%) | (68.45%) | (64.96%) | (26.13%) | (87.15%) | (23.11%) | |
ROIC |
— | 0.00% | 0.00% | (161.69%) | (153.63%) | 76.43% | (174.27%) | (0.51%) |
Return on Tangible Assets |
— | (4,795.50%) | (176.52%) | (71.90%) | (96.90%) | (39.75%) | (290.25%) | (69.91%) |
Average Days of Receivables |
— | 27.64 | 33.85 | 93.15 | 76.81 | 2,157.85 | 578.43 | 142.65 |
Research and Development Expense of Revenue |
— | 880.75% | 812.02% | 395.25% | 212.49% | 102.87% | 48.60% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 615.42% | 946.65% | 594.96% | 367.97% | 670.24% | 196.34% | 51.77% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.15 | 0.09 | 0.10 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 95.61% | 105.57% | 142.99% | 79.67% | 112.17% | 42.32% | 2.28% |
Graham Net Nets |
— | (1.52) | (1.52) | 0.26 | 0.64 | 1.50 | (1.41) | (8.21) |
Graham Number |
— | 0.00 | 1,044.88 | 0.00 | 0.00 | 0.00 | 1.38 | 1.69 |
Earnings Yield |
— | (507.09%) | (507.09%) | (211.93%) | (120.82%) | (104.32%) | (1,335.95%) | (545.33%) |
Free Cash Flow Yield |
— | (399.86%) | (399.86%) | (29.33%) | (112.22%) | (225.26%) | (1,036.62%) | (1,778.87%) |
Revenue per Share |
— | 3.97 | 4.22 | 0.74 | 0.60 | 0.11 | 0.25 | 0.68 |
Operating CF per Share |
— | (61.89) | (83.31) | (7.47) | (3.48) | (3.12) | (2.17) | (1.06) |
Capex per Share |
— | (3.73) | (19.93) | (0.98) | (0.35) | (0.01) | (0.01) | 0.00 |
Free Cash Flow per Share |
— | (65.62) | (103.25) | (8.45) | (3.83) | (3.13) | (2.18) | (1.07) |
Cash per Share |
— | 32.79 | 107.07 | 11.50 | 3.52 | 2.68 | 1.01 | 0.47 |
Shareholders Equity per Share |
— | (24.74) | 40.99 | 11.10 | 3.69 | 2.63 | (0.03) | (0.39) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (24.74) | 40.99 | 11.10 | 3.69 | 2.63 | (0.03) | (0.39) |
Free Cash Flow |
— | (35.82) | (69.38) | (96.39) | (109.65) | (89.14) | (63.34) | (31.77) |
Working Capital |
— | (2.92) | 50.55 | 129.48 | 107.78 | 98.00 | 27.31 | 13.14 |
Capital Expenditures |
— | (2.04) | (13.39) | (11.22) | (9.97) | (0.23) | (0.22) | (0.11) |
Net Current Asset Value |
— | (17.51) | 4.55 | 85.44 | 62.22 | 59.45 | (8.59) | (14.66) |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.94 | 4.72 | 1.33 | 0.58 | 0.08 | 0.03 | 0.01 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.96 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 1.36 | 4.65 | 0.42 | 0.70 | 8.42 | 0.02 | 3.73 |
Cash ROIC |
— | (118.39%) | (50.07%) | (32.37%) | (44.31%) | (47.93%) | (100.42%) | (90.79%) |
Accounts Receivable Turnover |
— | 10.15 | 13.28 | 6.99 | 5.96 | 0.28 | 0.49 | 2.10 |
Accounts Payable Turnover |
— | 2.74 | 3.37 | 2.62 | 4.17 | 0.99 | 3.94 | 9.48 |
Inventory Turnover |
— | 1.31 | 1.62 | 1.49 | 2.24 | 0.54 | 3.39 | 6.31 |
Average Days of Payables |
— | 77.62 | 153.30 | 189.89 | 83.35 | 182.68 | 97.83 | 24.33 |
Days of Inventory on Hand |
— | 145.95 | 332.66 | 297.67 | 181.90 | 132.53 | 151.58 | 34.13 |
Average Receivables |
— | 0.21 | 0.21 | 1.21 | 2.90 | 10.78 | 14.64 | 9.62 |
Average Payables |
— | 2.74 | 2.74 | 6.07 | 7.89 | 5.00 | 2.62 | 2.02 |
Average Inventory |
— | 5.71 | 5.71 | 10.69 | 14.68 | 9.10 | 3.04 | 3.03 |
Average Assets |
— | 12.97 | 65.70 | 149.00 | 181.16 | 151.62 | 93.70 | 41.30 |
Average Common Equity |
— | (178.82) | (178.82) | (49.61) | 116.15 | 90.37 | 37.07 | (6.24) |
Columns are period end dates